PROVIDENCE, R.I., Jan. 5, 2012 /PRNewswire/ -- Nabsys, Inc., has initiated its transition from technology development to product commercialization by announcing the appointment of Stan Rose, Ph.D., as the company's first chief commercial officer. Nabsys is also announcing that Jeffrey Sklar, M.D., Ph.D., has agreed to join the company's scientific advisory board.
Nabsys is pioneering the development of a novel technology with broad applicability for DNA analysis, called Positional Sequencing. The Nabsys platform uses solid-state nanodetectors to analyze single DNA molecules by electronic detection, revealing both location and identity of DNA sequences over long distances. Knowledge of the position of each DNA sequence greatly facilitates sequence assembly. Positional sequencing is inherently targeted, permitting focused analysis of particular regions of the genome varying in size from that of a single gene up to and including the entire genome.
Nabsys's positional sequencing platform is designed to set new standards for accuracy, speed and scalability of DNA sequence analysis. Major applications include analysis of genome structural variation, genome mapping, and both targeted and whole genome sequencing. Nabsys plans to develop a portfolio of tools based on positional sequencing, with a special focus on opportunities in cancer genomics research and diagnostics.
"These two appointments represent a significant milestone in our growth as a company and the implementation of our strategic vision," said Barrett Bready, M.D., president, CEO and director of Nabsys. "Stan has been deeply involved with Nabsys as a director for the company over the last two years. Stan's expanded involvement, combined with his experience in transforming innovative life science technologies into rapidly growing businesses, will be a great asset to Nabsys as we shift our focus towards commercial development. Dr. Sklar is a leadin
|SOURCE Nabsys, Inc.|
Copyright©2010 PR Newswire.
All rights reserved